ASCO 2023: Patient Outcomes Following Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell ALL
Posted: 06/20/2023 | By: Sarah Campen, PharmD

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Roloff et al presented findings on outcomes among 76 adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) treated with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel following its U.S. Food and Drug Administration (FDA) approval in October 2021 (Abstract 7001).

Question 1 of 5

Approval for brexucabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) was based on the phase II results of which clinical trial?

Choose 1